Kabadi Udaya M
Department of Veterans Affairs, VAMC, Iowa City, IA and Roy and Lucille Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Int J Diabetes Dev Ctries. 2008 Apr;28(2):65-8. doi: 10.4103/0973-3930.43102.
Several barriers to insulin therapy are encountered by both the providers and the patients with type 2 diabetes mellitus. These barriers include the fear of the needles i.e. number of injections as well as number of times of self blood glucose monitoring, fear of hypoglycemia and weight gain as well as the convenience, compliance and the cost. However, most of these patients are likely to require insulin therapy with increasing duration of the disorder because of the progressive cell failure. Therefore the most important aspect of insulin therapy must revolve around the regimen most suitable and acceptable because of its ability in overcoming these barriers while being effective in attaining and maintaining desirable glycemic control.
Recently published studies using different regimens with combinations of various oral agents and insulins in patients with type 2 DM and manifesting lapse of glycemic control when treated with various oral agents are discussed. Specific attention is paid to the capacity of each individual regimen in overcoming aforementioned barriers.
Comparative analysis amongst various insulin regimens shows that combination of metformin, and glimeperide with SC administration of basal insulin Lantus required the least daily dose of insulin with least consequential hypoglycemia as well as weight gain. Moreover, the number of injections as well as the number of times of self blood glucose monitoring, were lesser with this regimen with better compliance and more convenience in comparison to other combination insulin regimens.
The insulin regimen with fewest barriers consists of one SC injection of basal insulin lantus in combination with oral agents. However, to be effective, oral agents must include a secretogogue i.e. glimeperide in addition to a sensitizer i.e. metformin and not multiple sensitizers without a secretogogue. Moreover, this regimen apparently is also the most preferred by the patients, and is cost effective.
2型糖尿病患者和医护人员在胰岛素治疗方面都面临一些障碍。这些障碍包括对针头的恐惧,即注射次数以及自我血糖监测的次数、对低血糖和体重增加的恐惧,以及便利性、依从性和成本。然而,由于病情进展导致细胞逐渐衰竭,大多数这类患者可能随着病程延长而需要胰岛素治疗。因此,胰岛素治疗最重要的方面必须围绕最适合且可接受的治疗方案展开,因为该方案能够克服这些障碍,同时有效地实现并维持理想的血糖控制。
讨论了最近发表的一些研究,这些研究针对2型糖尿病患者使用不同的口服药物和胰岛素组合方案,且在使用各种口服药物治疗时出现血糖控制不佳的情况。特别关注了每种方案克服上述障碍的能力。
各种胰岛素方案的对比分析表明,二甲双胍、格列美脲与皮下注射基础胰岛素来得时联合使用时,每日所需胰岛素剂量最少,低血糖及体重增加的情况也最少。此外,与其他联合胰岛素方案相比,该方案的注射次数和自我血糖监测次数更少,依从性更好,便利性更高。
障碍最少的胰岛素治疗方案是皮下注射一次基础胰岛素来得时并联合口服药物。然而,要达到有效治疗,口服药物必须包括促分泌剂(即格列美脲)以及增敏剂(即二甲双胍),而不是只有多种增敏剂而没有促分泌剂。此外,该方案显然也是患者最青睐的,且具有成本效益。